glucagon--n(alpha)-trinitrophenyl-his(1)-homo-arg(12)- and Hyperglycemia

glucagon--n(alpha)-trinitrophenyl-his(1)-homo-arg(12)- has been researched along with Hyperglycemia* in 1 studies

Other Studies

1 other study(ies) available for glucagon--n(alpha)-trinitrophenyl-his(1)-homo-arg(12)- and Hyperglycemia

Article	Year
Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science (New York, N.Y.), 1982, Feb-26, Volume: 215, Issue:4536 The glucagon analog [l-N alpha-trinitrophenylhistidine, 12-homoarginine]-glucagon (THG) was examined for its ability to lower blood glucose concentrations in rats made diabetic with streptozotocin. In vitro, THG is a potent antagonist of glucagon activation of the hepatic adenylate cyclase assay system. Intravenous bolus injections of THG caused rapid decreases (20 to 35 percent) of short duration in blood glucose. Continuous infusion of low concentrations of the inhibitor led to larger sustained decreases in blood glucose (30 to 65 percent). These studies demonstrate that a glucagon receptor antagonist can substantially reduce blood glucose levels in diabetic animals without addition of exogenous insulin. Topics: Animals; Diabetes Mellitus, Experimental; Glucagon; Hyperglycemia; Male; Rats; Receptors, Cell Surface; Receptors, Glucagon; Structure-Activity Relationship	1982

Article

Year

Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist.

Science (New York, N.Y.), 1982, Feb-26, Volume: 215, Issue:4536

The glucagon analog [l-N alpha-trinitrophenylhistidine, 12-homoarginine]-glucagon (THG) was examined for its ability to lower blood glucose concentrations in rats made diabetic with streptozotocin. In vitro, THG is a potent antagonist of glucagon activation of the hepatic adenylate cyclase assay system. Intravenous bolus injections of THG caused rapid decreases (20 to 35 percent) of short duration in blood glucose. Continuous infusion of low concentrations of the inhibitor led to larger sustained decreases in blood glucose (30 to 65 percent). These studies demonstrate that a glucagon receptor antagonist can substantially reduce blood glucose levels in diabetic animals without addition of exogenous insulin.

Topics: Animals; Diabetes Mellitus, Experimental; Glucagon; Hyperglycemia; Male; Rats; Receptors, Cell Surface; Receptors, Glucagon; Structure-Activity Relationship

1982